Physician profile
Jonas A Cooper
NPI 1154499499
$21,129.54
in general payments reported to CMS, 2019-2025
30 companies · $9,398 in 2025
The $9,398 reported for 2025 was more than what 79% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,745 · 2020: $1,615 · 2021: $597 · 2022: $1,077 · 2023: $1,498 · 2024: $1,200 · 2025: $9,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,605 · Food and Beverage: $4,451 · Education: $39.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,605.00 |
| Food and Beverage | $4,451.33 |
| Education | $39.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $7,704.91 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,690.00 | 2019 | |
| Abbott Laboratories | $2,540.32 | 2019-2025 | Aveir, Ensite Precision, Jot Dx |
| Boston Scientific Corporation | $1,945.06 | 2019-2025 | Watchman Access System, Watchman Flx, Farapulse |
| Medical Device Business Services, INC. | $737.28 | 2020 | |
| Biosense Webster, INC. | $700.56 | 2019-2025 | Carto 3 |
| Medtronic, INC. | $437.07 | 2021-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $404.40 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $339.71 | 2019-2024 | |
| Pfizer INC. | $305.41 | 2019-2025 | |
| Medtronic Vascular, INC. | $243.22 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $192.08 | 2019-2025 | Eliquis, Camzyos |
| Impulse Dynamics (USA) INC. | $173.05 | 2022-2024 | Optimizer, Optimizer |
| Biotronik INC. | $150.12 | 2019-2021 | |
| Cvrx, INC. | $131.64 | 2022-2025 | Barostim Neo System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $70.74 | 2019-2022 | |
| Bardy Diagnostics, INC. | $54.00 | 2020-2022 | |
| Cordis US Corp. | $35.98 | 2025 | Mynx Control Venous |
| Altathera Pharmaceuticals LLC | $33.74 | 2022-2023 | Sotalol Hydrochloride |
| Cardiva Medical, INC. | $33.36 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Novartis Pharmaceuticals Corporation | $29.77 | 2019-2021 | |
| Lundbeck LLC | $26.46 | 2019-2020 | |
| Atricure, INC. | $26.25 | 2020 | |
| Zoll Circulation INC | $23.78 | 2025 | Downstream Cartridge, Catheter, Therox Ds2 Console |
| Kiniksa Pharmaceuticals International, Plc | $23.00 | 2024 | Arcalyst |
| Portola Pharmaceuticals, LLC | $20.52 | 2019 | |
| Heartflow, INC. | $19.44 | 2025 | |
| Vital Connect, INC | $15.35 | 2024 | Vitalpatch Rtm |
| Angiodynamics, INC. | $11.33 | 2020 | |
| Philips North America LLC | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonas Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.